Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

FDMT US Equity

4D Molecular Therapeutics, Inc.Health Care · Biological Products, (No Diagnostic Substances) · CIK 1650648 · FY ends Dec 31
$16.76
+2.04 (+13.86%)
USD · as of 2026-08-19 · marketstack

Legal & controls

5 of 5 annual reports readable here

Item 3 and Item 9A as filed · every verdict is the registrant’s own sentence, printed below it · a filing that fails an extraction gate reads “not extracted”

Fiscal yearFiledItem 3ICFRdisclosure controlsmaterial weaknessFiling
2025-12-312026-03-18none statedeffectiveeffectivenone in Item 9AEDGAR

Item 3 · We are not currently a party to any material legal proceedings. From time to time, the Company may become involved in legal proceedings arising from the ordinary course of its business. If applicable, the Company records a liability for such matters when it believes that it is both probable that a liability may have been incurred, and the amount of the liability can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the estimated amount. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 9A · ICFR · Based on our evaluation, management has concluded that our internal control over financial reporting was effective as of December 31, 2025.

Item 9A · disclosure controls · Based upon such evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.

2024-12-312025-02-28none statedeffectiveeffectivenone in Item 9AEDGAR

Item 3 · We are not currently a party to any material legal proceedings. From time to time, the Company may become involved in legal proceedings arising from the ordinary course of its business. If applicable, the Company records a liability for such matters when it believes that it is both probable that a liability may be imputed, and the amount of the liability can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the estimated amount. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 9A · ICFR · Based on this assessment, management has determined that our internal control over financial reporting as of December 31, 2024 was effective.

Item 9A · disclosure controls · Management’s Evaluation of our Disclosure Controls and Procedures and Internal Control Over Financial Reporting Evaluation of Disclosure Controls and Procedures Based on the evaluation of our disclosure controls and procedures (as defined under Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended) required by Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended, our Chief Executive Officer and our Chief Financial Officer have concluded that as of December 31, 2024, the end of the period covered by this report, our disclosure controls and procedures were effective.

2023-12-312024-02-29none statedeffectiveeffectivenone in Item 9AEDGAR

Item 3 · We are not currently a party to any material legal proceedings. From time to time, the Company may become involved in legal proceedings arising from the ordinary course of its business. If applicable, the Company records a liability for such matters when it believes that it is both probable that a liability may be imputed, and the amount of the liability can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the estimated amount. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 9A · ICFR · Based on our evaluation, management has concluded that our internal control over financial reporting was effective as of December 31, 2023.

Item 9A · disclosure controls · Based upon such evaluation, our principal executive officer and principal financial and accounting officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.

2022-12-312023-03-15none statedeffectiveeffectivenone in Item 9AEDGAR

Item 3 · We are not currently a party to any material legal proceedings. From time to time, the Company may become involved in legal proceedings arising from the ordinary course of its business. If applicable, the Company records a liability for such matters when it believes that it is both probable that a liability may be imputed, and the amount of the liability can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the estimated amount. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 9A · ICFR · Based on our evaluation, management has concluded that our internal control over financial reporting was effective as of December 31, 2022.

Item 9A · disclosure controls · Based upon such evaluation, our principal executive officer and principal financial and accounting officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.

2021-12-312022-03-28none statedeffectiveeffectivenone in Item 9AEDGAR

Item 3 · We are not currently a party to any material legal proceedings. From time to time, the Company may become involved in legal proceedings arising from the ordinary course of its business. If applicable, the Company records a liability for such matters when it believes that it is both probable that a liability may be imputed, and the amount of the liability can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the estimated amount. Regardless of outcome litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 9A · ICFR · Based on our evaluation, management has concluded that our internal control over financial reporting was effective as of December 31, 2021.

Item 9A · disclosure controls · Based upon such evaluation, our principal executive officer and principal financial and accounting officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.

5 of 5 annual reports on record have their filing text cached on this host; the rest are listed with their EDGAR link and no extraction, because this surface never fetches from SEC on a page load.

  • Item 3 and Item 9A are located in the filing HTML already cached on this host and read with the same line-anchored item matcher and largest-gap body disambiguation the filing-narrative pass uses for Item 1A and Item 7 — no fetch, no model, no summarization.
  • A heading is accepted as a section only when it is not a table-of-contents row (a trailing page number), not a quoted reference in prose, and names its own section; the span must then clear a per-item length band and carry readable text after the heading. Anything that fails a gate is served as 'not extracted' with the reason — never as a default value.
  • An effectiveness conclusion is read only from a sentence that names its own control set (disclosure controls and procedures, or internal control over financial reporting) and states an outcome. Conditional sentences — the standard limitations paragraph and forward-looking remediation language — are excluded, because they are hypotheses rather than conclusions.
  • When a filing's own sentences disagree — an effective conclusion beside an unremediated material-weakness disclosure, or two conclusions of opposite sign — no verdict is asserted. A wrong 'controls were effective' reading is worse than no reading.
  • Every verdict is shown beside the verbatim sentence it was read from. The excerpt is the filing's own words, capped at 1,200 characters; the filing itself is one link away.